SubsidieMeestersTargeting cancer with mutanome based stem cell vaccine
MUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines.
Projectdetails
Introduction
The successful application of immune checkpoint inhibitors has modified the therapeutic strategies in several cancers, but only 30% of patients will respond optimally to these therapies. One of the reasons for the failure of these therapies is the resistance of cancer stem cells (CSCs), leading to relapses long after the initial treatment.
Challenges of Cancer Stem Cells
These cells are also resistant to conventional therapies via their quiescence, and there are no targeted therapies available against them.
IPSIRIUS Overview
The ambition of IPSIRIUS, a French biotechnology company and spinoff of INSERM and Paris Saclay University, is to develop active cancer immunotherapy products based on the revolutionary induced pluripotent stem cell (iPSC) technology.
IPVAC Development
IPSIRIUS developed the first IPVAC, with the aim of leveraging the patient’s immune system against a large panel of cancer antigens that are shared between iPSCs and CSCs.
Technology and Safety
With IPVAC, IPSIRIUS is developing a ground-breaking technology, having resolved all technical issues limiting cell-based therapies used for cancer. IPVAC is a safe, allogenic, off-the-shelf therapy, highly scalable using a versatile technology.
Efficacy
This cell-based vaccination strategy has shown efficacy in prophylactic and therapeutic settings against aggressive solid cancers with stemness features.
Goals of the MUTAVAC Project
The overall goal of the MUTAVAC project is to:
- Uncover the mechanisms of action of IPVAC.
- Generate a highly immunogenic version of IPVAC.
- Design robust in vitro immunogenicity tests to predict the immunogenicity of IPVAC and IPVAC-Mut in humans.
Outcomes of the MUTAVAC Project
With the MUTAVAC project, IPSIRIUS will:
- Strengthen the scientific data on IPVAC to prepare for its clinical development, leading to open access publications and patents.
- Define a personalized medicine to propose an efficient therapeutic cancer vaccine for patients with all HLA groups.
- Identify new targets for future cancer therapies.
- Develop a technological platform to facilitate the development of the next generation of cell therapies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.782.000 |
| Totale projectbegroting | € 1.809.500 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- IPSIRIUSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC POC | € 150.000 | 2023 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC POC | € 150.000 | 2023 | Details |
Targeting Cancer with ERV VaccinesInProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerAdjuTec-Therapeutics ontwikkelt een gepersonaliseerde immunotherapie, PanCaVax, voor alvleesklierkanker om de overlevingskansen van patiënten na operatie te verbeteren en streeft naar OD-status voor versnelde registratie. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Targeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
AdjuTec-Therapeutics ontwikkelt een gepersonaliseerde immunotherapie, PanCaVax, voor alvleesklierkanker om de overlevingskansen van patiënten na operatie te verbeteren en streeft naar OD-status voor versnelde registratie.